Email ID : 
Password : 
Forgot Your Password ? 

Only Report Titles
Titles & Keywords
NOTE: Site best viewed with Internet Explorer
  OPTHALMIC PHARMACEUTICAL DRUGS
A Global Strategic Business Report

This report analyzes the worldwide markets for Opthalmic Pharmaceutical Drugs in US$ Million. The major therapeutic categories analyzed are Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 96 companies including many key and niche players worldwide such as Akorn, Inc., Alcon Eye Care, Inc., Allergan, Inc., Alimera Sciences, Inc., Bausch & Lomb, Inc., Genvec, Inc., GlaxoSmithKline Plc, Inspire Pharmaceuticals, Inc., ISTA Pharmaceuticals, Inc., Merck & Co., Inc., Novartis Ophthalmics, Opko Health, Inc., Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., QLT, Inc., Santen Pharmaceutical Co., and Santen Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

CODE:    MCP-1490  PAGES:    523
PRICE:    $3950  DATE:       April 2008
COMPANIES:  96  MARKET DATA TABLES:   199
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

 TABLE OF CONTENTS  
  OPTHALMIC PHARMACEUTICAL DRUGS (Complete Report) Pages : 523   | $3950
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS3$100
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
Quantitative Techniques & Analytics.....I-2
  
   Product Definitions and Scope of Study.....I-3  
II. EXECUTIVE SUMMARY118$2250
  1. Industry Overview.....II-113 $800  
   A Curtain Raiser.....II-1
Drugs Developed in the Recent Past.....II-1
1$100
   What the Future Holds in Store?.....II-2
Where Does the Opportunity Lie?.....II-2
In the Shifting Demographics .....II-2
1$100
   Which Disease Segment Offers Abundant Opportunities for R&D Initiatives.....II-31$100
   Leading Companies & Their Areas of Research Interest/Focus.....II-4
Business Opportunities in Ophthalmology: A Fact Sheet.....II-4
Impediments in Picking the Ripe & Low Hanging Opportunities.....II-4
Low Patient Compliance.....II-4
1$100
   What’s the Antidote to Low Patient Compliance?.....II-5
Innovation in Ophthalmic Pharmaceuticals: How Does It Help Patients?.....II-5
1$100
   An Unequivocal Discussion About Ocular Drug Design and Delivery.....II-6
Why Understanding of the Metabolic Activity of the Eye is Important?.....II-6
1$100
   Pitfalls of Traditional Ocular Treatment.....II-7
Ophthalmic Drug Delivery: A Recapitulation of Facts.....II-7
1$100
   Antidotes to Low Delivery of Ocular Drugs & High Side Effects.....II-81$100
   Prodrug.....II-9
Soft Drugs (SDs).....II-9
Soft Corticosteroids.....II-9
1$100
   Drug Penetration Enhancers.....II-10
Chitosan Based Drugs & Drug Delivery Systems.....II-10
How Chitosan is used to Improve Ocular Drug Retention On the Eye’s Surface?.....II-10
1$100
   The Future of Ophthalmic Drug Delivery.....II-11
A Straight Talk About Ophthalmic Drug Delivery Technologies.....II-11
High Flying Expectations of Blistering Pace of Drug Development Grounded.....II-11
1$100
   First Generation Advancements Made in Ocular Drugs.....II-12
Second Generation Advancements Made in Ocular Drugs.....II-12
1$100
   Limiting Factors.....II-13
1$100
  2. Market Dynamics.....II-145 $500  
   Ophthalmic Pharmaceuticals Poised to Encounter Days of Plenty .....II-14
Ophthalmic Inserts Flaunt the Potential to Eclipse the Popularity of Eye Drops.....II-14
1$100
   Rising Incidences of Glaucoma: A Business Case for Ophthalmic Drugs.....II-15
Aging Population & Environmental Factors Drive Growth.....II-15
Increase in Health Care Spending.....II-15
1$100
   Opportunities Abound in the Developing Countries.....II-16
Innovative Products Lend Traction to Growth.....II-16
Reimbursements: “Under the Umbrella”.....II-16
1$100
   Pricing Statistics On Select Ophthalmic Drugs in the United States for the Year
  2006.....II-17
1$100
   Price Changes for Select Ophthalmic Drugs in the Year 2005.....II-18
1$100
  3. An Overview of Ophthalmic Drugs.....II-1929 $1100  
   Anti Viral Drugs.....II-19
Adenoviral Infections.....II-19
Herpes Simplex Virus.....II-19
Herpes Zoster (Varicella Zoster Disease).....II-19
Corticosteroids.....II-19
1$100
   Loteprednol.....II-20
Prednisolone.....II-20
1$100
   Dexamethasone.....II-21
Fluorometholones.....II-21
Fluorometholone Alcohol.....II-21
Fluorometholone Acetate.....II-21
1$100
   Rimexolone.....II-22
Clinical Efficacy of Steroids.....II-22
Topical Corticosteroid Drugs.....II-22
1$100
   Tapering of Steroid Intake.....II-23
Non-Steroids Anti Inflammatory Drugs (NSAID).....II-23
1$100
   Use of Topical NSAIDs.....II-24
Topical & Systemic NSAIDs.....II-24
Ketorolac: A Potent NSAID.....II-24
Non-Steroidal Anti-Inflammatory Drugs.....II-24
1$100
   Antibiotics.....II-25
Sodium Sulfacetamide.....II-25
Sulfisoxazole.....II-25
1$100
   Bacitracin.....II-26
Bacitracin and Polymyxin B: A Powerful Duo.....II-26
Bacitracin, Polymyxin B and Neomycin: Three To Tango.....II-26
Trimethoprim with Polymyxin B.....II-26
1$100
   Chloramphenicol.....II-27
Erythromycin.....II-27
Gentamicin and Tobramycin.....II-27
1$100
   Fluoroquinolones.....II-28
Types of Fluoroquinolones.....II-28
Ciprofloxacin.....II-28
Gatifloxacin.....II-28
Levofloxacin.....II-28
1$100
   Moxifloxacin.....II-29
Ofloxacin.....II-29
Topical Antibiotic Drugs.....II-29
1$100
   Ophthalmic Antihistamines.....II-30
Azelastine.....II-30
Emedastine.....II-30
Epinastine.....II-30
Ketotifen.....II-30
Olopatadine.....II-30
1$100
   Ophthalmic Mast-Cell Stabilizers.....II-31
Cromolyn.....II-31
Nedocromil Sodium.....II-31
Pemirolast.....II-31
Drugs to Treat Glaucoma.....II-31
Beta-Adrenergic Blockers or "Beta Blockers".....II-31
1$100
   Timolol.....II-32
Levobunolol.....II-32
Carteolol.....II-32
Metipranolol.....II-32
1$100
   Betaxolol.....II-33
Alpha-Adrenergic Agonists.....II-33
Carbonic Anhydrase Inhibitors.....II-33
1$100
   Acetazolamide.....II-34
Dorzolamide.....II-34
Acetazolamide & Dorzolamide: How Good Is the Combo?.....II-34
Miotics.....II-34
Prostaglandins.....II-34
1$100
   Mydriatics & Cycloplegics.....II-35
Side Effects.....II-35
1$100
   Over-The-Counter (OTC) Ophthalmic Preparations.....II-36
Artificial Tears.....II-36
Lubricating Ointments.....II-36
Mast Cell Stabilizers.....II-36
1$100
   Antihistamines.....II-37
Phenylephrine.....II-37
Naphazoline.....II-37
Xylometazoline.....II-37
Astringents.....II-37
1$100
   Over-The-Counter Ophthalmic Preparations.....II-381$100
   A Directory Listing of Major Ophthalmic Pharmaceutical Drugs.....II-39
Formulary Anti- Glaucoma Drugs.....II-39
1$100
   Non-Formulary Anti- Glaucoma Drugs.....II-40
Formulary Topical Anti-Glaucoma Drugs.....II-40
1$100
   Formulary Ophthalmic Antiinfective/Corticosteroids Drugs.....II-41
Non-Formulary Ophthalmic Antiinfective/ Corticosteroids Drugs.....II-41
1$100
   Formulary Ophthalmic Corticosteroid Drugs.....II-42
Non-Formulary Ophthalmic Corticosteroid Drugs.....II-42
1$100
   Formulary Ophthalmic Topical Antibacterial Drugs.....II-431$100
   Non-Formulary Ophthalmic Topical Antibacterial Drugs.....II-44
Formulary Ophthalmic Topical Antiviral Drugs.....II-44
Other Ophthalmic Formulary Drugs.....II-44
1$100
   Other Ophthalmic Non-Formulary Drugs.....II-452$200
   New Drugs In the Pipeline.....II-47
1$100
  4. Ophthalmic Disorders: A Freeze Frame.....II-4820 $1000  
   The Human Eye: A Remarkable & Intriguing Organ of Sight.....II-48
The Outer Layer.....II-48
The Middle Layer.....II-48
1$100
   The Inner Layer.....II-49
Common Ophthalmic Disorders: An Exposition.....II-49
Cataract.....II-49
Causes.....II-49
1$100
   Types of Cataract.....II-50
Treatment Strategies.....II-50
1$100
   How Widespread is the Disease?.....II-51
Glaucoma.....II-51
Who’s At Risk?.....II-51
1$100
   Types of Glaucoma.....II-52
Primary Open Angle Glaucoma (POAG).....II-52
Acute Angle-Closure Glaucoma (AACG).....II-52
Congenital Glaucoma.....II-52
1$100
   Secondary Glaucoma.....II-53
Treatment Strategies.....II-53
1$100
   Anti- Glaucoma Ophthalmic Drugs.....II-54
How Widespread is the Disease?.....II-54
1$100
   Table 1: Prevalence of Glaucoma in the World: Year 1999 and 2006 A Comparison (In 000 Individuals) (includes corresponding Graph/Chart).....II-551$350
   Is Marijuana A Potential Cure?.....II-56
Age-Related Macular Degeneration (AMD).....II-56
Types of AMD.....II-56
Dry AMD (Non-Neovascular).....II-56
Wet AMD (Neovascular).....II-56
1$100
   Causes.....II-57
Treatment Strategies.....II-57
1$100
   Nutrition & AMD.....II-58
Diabetic Retinopathy.....II-58
Treatment Strategies.....II-58
1$100
   How Widespread is the Disease?.....II-59
Ocular Allergies.....II-59
Treatment Strategies.....II-59
1$100
   Immunotherapy: A Popular Anti-Allergy Treatment Approach.....II-60
Ocular Inflammation: A Symptom of Ocular Allergies.....II-60
1$100
   How Can Allergies Be Prevented?.....II-61
Conjunctivitis (Pink Eye).....II-61
1$100
   Types of Conjunctivitis.....II-62
Pathogenesis.....II-62
Treatment Strategies.....II-62
1$100
   Keratitis.....II-63
Types of Keratitis.....II-63
1$100
   Treatment Strategies.....II-64
Dry Eye.....II-64
1$100
   Why Are Tears So Crucial for Normal Eye Health?.....II-65
What Causes Dry Eye?.....II-65
Treatment Strategies.....II-65
1$100
   Refractive Errors.....II-66
Causes for Refractive error.....II-66
Treatment for Refractive Errors.....II-66
1$100
   Cost of Treatment.....II-67
Factors contributing to the Difference in Surgery Costs.....II-67
1$100
  5. FDA Regulations and Approvals.....II-686 $400  
   Novagali Obtains FDA Approval of Nova22007 IND for Ph III Trial.....II-68
Alimera Conducts Phase III Medidur Trial.....II-68
ISTA Pharmaceuticals Files NDA for Xibrom™ QD.....II-68
AzaSite Receives FDA Approval.....II-68
1$100
   Alimera Sciences Receives FDA Approval.....II-69
Alcon Receives Approval for Vegamox™ Ophthalmic Solution in Japan.....II-69
Alcon Receives Marketing Approval for Patanol® in Japan.....II-69
Allergan Receives FDA Approval for Lumigan®.....II-69
Allergan’s Ganfort® Receives Pan European License.....II-69
1$100
   Pfizer Receives Approval from EC to Market Macugen®.....II-70
Akorn Gets Nod for Conducting Clinical Trial of AK-1015.....II-70
Genentech ‘s Lucentis Receives FDA Approval.....II-70
MacuSight Receives FDA Approval for IND Application of Sirolimus.....II-70
Sami Labs Receives Approval for Ocufors.....II-70
Toyamo and Nidek Obtain Manufacturing Approval for Quinolone Ophthalmic
  Solutions.....II-70
1$100
   Alcon's NEVANAC Receives FDA Approval.....II-71
Fougera Obtains Approval for MetroGel®.....II-71
Allergan’s Alphagan P Receives FDA Approval.....II-71
Santen Obtains Approval for Manufacturing and Marketing PAPILOCK.....II-71
Alcon Receives FDA Approval for Adding Susceptible Pathogens to VIGAMOX.....II-71
BOL Receives FDA Approval for Ofloxacin.....II-71
1$100
   Hi-Tech Pharmacal Receives FDA Clearance for Ofloxacin Ophthalmic Solution.....II-72
Vision Blue and DORC International Receives FDA Approval for Trypan Blue.....II-72
Pfizer Receives FDA Nod for Macugen®.....II-72
Bausch & Lomb Bags FDA Approval for its Zylet™.....II-72
Alcon Receives Approval for Olopatadine (Patanol).....II-72
Pharmacia Receives FDA Approval for Latanoprost Ophthalmic Solution.....II-72
1$100
   US FDA Approves Allergan’s New Acular LS 0.4% for Ocular Pain Reduction.....II-73
Allergan Obtains FDA Approval for Zymar.....II-73
1$100
  6. Product Innovations/Introductions.....II-743 $300  
   Inspire Pharmaceuticals Rolls Out AzaSite™ for Ocular Infections.....II-74
Reckitt Benckiser Launches Two Eye Care Products.....II-74
Alcon Launches DUOTRAV for Glaucoma Treatment.....II-74
Rohto Pharmaceutical Launches Switch OTC Ophthalmic Drug.....II-74
Indoco Remedies to Launch Ophthalmic Drugs in America.....II-74
Akorn Launches Ophthalmic Drug Products.....II-74
1$100
   AlphaRx Formulates the Ophthalmic Product, Binoxan™.....II-75
Alimera Sciences Introduces Online Consumer Ordering Facility.....II-75
Fougera Adds Two Novel Products to its Ophthalmic Product Line.....II-75
Micro Vision Launches Anti-Glaucoma Drugs.....II-75
ISTA Pharmaceuticals Launches Istalol for Glaucoma Treatment in the US.....II-75
Falcon Unveils Trifluridine Ophthalmic Solution, 1%.....II-75
Alimera Sciences Unveils Soothe™ Emollient Eye Drops.....II-75
1$100
   Novartis Introduces Zaditen in Japan.....II-76
Falcon Releases Brimonidine Tartrate Ophthalmic Solution, 0.2%.....II-76
Taiwanese Researchers Introduces Thermosensitive Ophthalmic Drop.....II-76
Alcon Introduces Systane Lubricant Eye Drops.....II-76
Allergan Releases Restasis for Dry Eye Treatment.....II-76
Biosyntrx Launches BioTears.....II-76
Novartis to Introduce Pirenzepine Ophthalmic Gel.....II-76
1$100
  7. Recent Industry Activity.....II-7711 $700  
   Bausch & Lomb Acquires IOL Maker, Eyeonics.....II-77
Akorn Inks Manufacture &Supply Agreement for Ophthalmic Solution.....II-77
CrystalGenomics Enters Into R&D Agreement with Bausch & Lomb.....II-77
Genaera Corporation Quits Evizon Clinical Trials.....II-77
Eyetech Inc Divests Anti-Platelet Derived Growth Factor (PDGF) Aptamer Program.....II-77
Amneal, Indoco Agree to Develop & Market Generic Ophthalmic Drugs.....II-77
1$100
   Bausch & Lomb Acquire Soothe Products from Alimera.....II-78
Froptix, Acuity, eXegenics Merge to Form Opko Corporation.....II-78
Alimera, Emory Collaborate Over Potential Ophthalmic Treatments Using Novel
  Antioxidants.....II-78
1$100
   Santen Signs Agreement with Vistakon Pharmaceuticals for US Launch of Iquix®.....II-79
Inspire Pharmaceuticals Rolls Out AzaSite™ for Ocular Infections.....II-79
QLT Takes Over Forsight Newco II, Inc.....II-79
Phase IV Clinical Trials Of Macugen®.....II-79
Results Of Phase II Clinical Trials – Macugen®.....II-79
1$100
   Macugen® Receives European Regulatory Approval.....II-80
Bausch & Lomb Purchases OTC Allergy Drugs of Alimera.....II-80
Phase II Trial of Acuity Pharmaceutical’s Bevasiranib.....II-80
Advanced Refractive Technologies Acquires a Subsidiary of UTEK Corporation.....II-80
1$100
   Sirion Therapeutics Acquires Sytera.....II-81
Teva Pharmaceuticals Acquires Ivax.....II-81
Alcon Enters into an Agreement with Amgen.....II-81
QLT Signs an Agreement with Retinagenix.....II-81
NicOx Enters into Licensing Agreement with Pfizer.....II-81
OccuLogix Signs Agreement to Acquire SOLX.....II-81
1$100
   ISTA Receives License from Senju for Allergy Treatments.....II-82
Acuity Receives License for Nchlorotaurine.....II-82
Akorn and AVR Enter into Commercial Manufacturing & Supply Agreement.....II-82
Lantibio Signs Agreement with TRB Chemedica.....II-82
Argentis and Southern College of Optometry Enter into Agreement.....II-82
Bausch & Lomb Enters into Marketing Agreement with Novartis.....II-82
Santen Pharmaceuticals and Ube Industries to Develop Glaucoma Therapy Jointly.....II-82
1$100
   Santen Pharmaceutical and CytoPathfinder Signs an Agreement.....II-83
Kalypsys Inks an Agreement with Alcon, Inc.....II-83
Combination RX Enters into a Collaboration Agreement with Fovea.....II-83
Par Pharmaceutical Joins Force with Spectrum Pharmaceuticals.....II-83
Isotechnika Sells Eye Drug Rights to Lux Biosciences.....II-83
Alimera Sciences Collaborates With CYNACON.....II-83
1$100
   Novartis Inks an In-Licensing Agreement with Otsuka.....II-84
Alimera Sciences Commences Phase III Trials for Medidur™.....II-84
SurModics Acquires InnoRx.....II-84
Bausch & Lomb Acquires Shandong Chia Tai Freda Pharmaceutical Group.....II-84
OSI Pharmaceuticals Takes Over Eyetech Pharmaceuticals.....II-84
1$100
   Pfizer Acquires Angiosyn.....II-85
Bausch & Lomb Collaborates with PTC Therapeutics.....II-85
AMRI Enters into Research Collaboration with Alcon.....II-85
Bausch & Lomb Bags License from Cephalon.....II-85
PediaMed and Allergan Sign a Co-Promotion Agreement.....II-85
SurModics Bags Option to Acquire Exclusive Rights from Rutgers University.....II-85
Sankyo Co. and Santen Pharmaceutical Sign Agreement.....II-85
1$100
   Acuity Pharmaceuticals Enters into Agreement with Intradigm Corporation.....II-86
Apotex Inks Marketing Agreement with Akorn.....II-86
Novartis Enters into an Agreement with Senju Pharmaceutical.....II-86
Novartis Strikes a Licensing Deal with Otsuka Pharmaceutical.....II-86
Custom RX recalls Trypan Blue 0.06% Ophthalmic Solution.....II-86
AMO Takes Over VISX.....II-86
Advanced Medical Optics Acquires Ophthalmic Surgical Business of Pfizer.....II-86
1$100
   Santen to Take Over Marketing Rights of Rescula from R-Tech Ueno.....II-87
Alimera Sciences Inks Co-promotion Agreement with VISTAKON Pharmaceuticals.....II-87
Akorn Inks a Purchase and Supply Agreement with FDC.....II-87
ISTA Pharmaceuticals Receives Marketing License From Senju Pharmaceuticals.....II-87
Pfizer Inc Acquires Pharmacia Corp.....II-87
Allergan Takes Over Oculex Pharmaceuticals.....II-87
Allergan Enters into an Agreement with Acadia.....II-87
1$100
  8. Focus on Select Global Players.....II-887 $700  
   Akorn, Inc. (USA).....II-88
Alcon Eye Care, Inc. (USA).....II-88
1$100
   Allergan, Inc. (USA).....II-891$100
   Alimera Sciences, Inc. (USA).....II-90
Bausch & Lomb, Inc. (USA).....II-90
1$100
   Genvec, Inc. (USA).....II-91
GlaxoSmithKline Plc (UK).....II-91
Inspire Pharmaceuticals, Inc. (USA).....II-91
ISTA Pharmaceuticals, Inc. (USA).....II-91
1$100
   Merck & Co., Inc. (USA).....II-92
Novartis Ophthalmics (Canada).....II-92
1$100
   Opko Health, Inc (USA).....II-93
Otsuka Pharmaceutical Co., Ltd. (Japan).....II-93
Pfizer Inc. (USA).....II-93
QLT, Inc. (Canada).....II-93
1$100
   Santen Pharmaceutical Co. (Japan).....II-94
Santen Inc. (USA).....II-94
1$100
  9. Global Market Perspective.....II-95   
   Table 2: World Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-951$350
   Table 3: World Long-term Projections for Ophthalmic Pharmaceutical Drugs by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-961$350
   Table 4: World 10-Year Perspective for Ophthalmic Pharmaceutical Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart).....II-971$350
   Table 5: World Recent Past, Current and Future Analysis for Glaucoma by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-981$350
   Table 6: World Long-term Projections for Glaucoma by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-991$350
   Table 7: World 10-Year Perspective for Glaucoma by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart).....II-1001$350
   Table 8: World Recent Past, Current and Future Analysis for Anti-allergy by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-1011$350
   Table 9: World Long-term Projections for Anti-Allergy by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-1021$350
   Table 10: World 10-Year Perspective for Anti-allergy by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart).....II-1031$350
   Table 11: World Recent Past, Current and Future Analysis for Anti-infective by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-1041$350
   Table 12: World Long-term Projections for Anti-Infective by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-1051$350
   Table 13: World 10-Year Perspective for Anti-infective by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart).....II-1061$350
   Table 14: World Recent Past, Current and Future Analysis for Dry Eye by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-1071$350
   Table 15: World Long-term Projections for Dry Eye by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-1081$350
   Table 16: World 10-Year Perspective for Dry Eye by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart).....II-1091$350
   Table 17: World Recent Past, Current and Future Analysis for Anti-inflammation by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-1101$350
   Table 18: World Long-term Projections for Anti-Inflammation by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-1111$350
   Table 19: World 10-Year Perspective for Anti-inflammation by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart).....II-1121$350
   Table 20: World Recent Past, Current and Future Analysis for Back of Eye by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-1131$350
   Table 21: World Long-term Projections for Back of Eye by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-1141$350
   Table 22: World 10-Year Perspective for Back of Eye by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart).....II-1151$350
   Table 23: World Recent Past, Current and Future Analysis for Other Treatment Category by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-1161$350
   Table 24: World Long-term Projections for Other Treatment Category by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-1171$350
   Table 25: World 10-Year Perspective for Other Treatment Category by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart).....II-1181$350
III. MARKET93$1950
  1. The United States.....III-142 $1575  
   A. Market Analysis.....III-1
Outlook.....III-1
Emphasis on Greater Awareness About Ophthalmic Disorders.....III-1
Growth Drivers In a Capsule.....III-1
Impediments to Growth.....III-1
1$75
   Market Fact Sheet.....III-2
Glaucoma Market: A Primer.....III-2
1$75
   Awareness Among Patients.....III-3
High Costs.....III-3
Treatment Patterns Adopted By Doctors.....III-3
The All Consuming Issue of Compliance.....III-3
1$75
   Drug Brands & Their Patience Compliance Scores......III-4
Market Share Statistics.....III-4
The New Batting Order.....III-4
Table 26: The US Market for Ophthalmic Pharmaceutical Drugs (2004-2007): Percentage Market Share Breakdown of Leading Players - Alcon Laboratories, Allergan, Novartis Pharmaceutical, Pfizer/OSI Pharmaceuticals, Bausch & Lomb Pharmaceuticals, and Others (includes corresponding Graph/Chart).....III-4
1$200
   Table 27: Top 10 Brands of Eye/Lens Care in the US: Breakdown of Dollar and Unit Sales Through Drug Stores, Supermarkets and Discount Stores For the Year Ended November 2007 (In US$ 000 and Thousand Units).....III-5

Table 28: Top 5 Eye Care Products in the US: Breakdown of Dollar Sales Through Food, Drug and Mass Market Channels for the Year Ended July 2007 (In US$ Million) (includes corresponding Graph/Chart).....III-5
1$200
   Table 29: Age-Related Wet Macular Degeneration Market in the United States (2004-2006): Percentage Market Share Breakdown of Leading Players - QLT Inc/Novartis Pharmaceutical Corp, and Eyetech Pharmaceuticals (OSI) / Pfizer......III-6

Table 30: Ocular Allergy Market in the United States (2004-2007): Percentage Market Share Breakdown of Leading Players - Alcon Laboratories, Novartis Pharmaceutical, Bausch & Lomb Pharmaceuticals, Allergan, Santen, and Others (includes corresponding Graph/Chart).....III-6
1$200
   Table 31: Ocular NSAIDs (Topical Non-Steroidal Anti-Inflammatory Drugs) Market in the United States (2005 & 2006): Percentage Market Share Breakdown of Leading Players - Allergan, Inc. Novartis Pharmaceutical Corp., Alcon Laboratories, Inc., and ISTA Pharmaceuticals (includes corresponding Graph/Chart).....III-7

Table 32: Age-Related Macular Degeneration Market in the United States (2006, 2009 & 2012): Dollar Sales of Major Branded Drugs – Visudyne, Macugen, and Lucentis (In US$ Million) (includes corresponding Graph/Chart).....III-7
Age-Related Macular Degeneration Market in the United States (2006) – New Brands
  Expected to hit the Market.....III-7
1$200
   Update On Drugs & Their Manufacturers in the US.....III-8
Patent Expirations of Key Ophthalmic Product Brands in the United States.....III-8
Major Anti-Glaucoma Drugs Available in the United States: Year 2006.....III-8
1$75
   Major Drugs Available in the United States for the Treatment of AMD: Year
  2005.....III-9
Drugs in the Pipeline for the Treatment of AMD in the United States: Year
  2005.....III-9
Major Drugs Available in the United States for the Control of Dry Eye: Year
  2005.....III-9
1$75
   US Market for Dry Eye: Drugs in the Pipeline Year 2005.....III-10
Companies Actively Involved in Manufacturing Drugs for Dry Eye: Year 2005.....III-10
Major Drugs Available in the United States for the Treatment of Ocular Allergies:
  Year 2005.....III-10
1$75
   US Market for Ocular Allergies: Drugs in the Pipeline: Year 2005.....III-111$75
   Statistical Findings On Ophthalmic Diseases in the United States.....III-12
Table 33: Prevalence of Age-Related Macular Degeneration: Percentage Breakdown by Wet AMD & Intermediate Dry AMD by Age Group for the Year 2005 (includes corresponding Graph/Chart).....III-12

Table 34: Prevalence of Age-Related Wet Macular Degeneration in the United States for the Years 2006, 2009, & 2012 (In Millions of Individuals) (includes corresponding Graph/Chart).....III-12

Table 35: Number of Individuals Treated for Wet AMD in the United States (In Thousands) for the Years 2006, 2009 & 2012 (includes corresponding Graph/Chart).....III-12
1$200
   Table 36: Prevalence of Ocular Hypertension (OHT) in the United States for the Years 2006, 2009, & 2011 (In Millions of Individuals) (includes corresponding Graph/Chart).....III-13

Table 37: Prevalence of Primary Open Angle Glaucoma (POAG) in the United States for the Years 2006, 2009, & 2011 (In Millions of Individuals) (includes corresponding Graph/Chart).....III-13

Table 38: Prevalence of Normal Tension Glaucoma (NTG) in the United States for the Years 2006, 2009, & 2011 (In Thousand Individuals) (includes corresponding Graph/Chart).....III-13

Table 39: Prevalence of Exfoliative Glaucoma (EG) in the United States for the Years 2006, 2009, & 2011 (In Thousand Individuals) (includes corresponding Graph/Chart).....III-13
1$200
   Table 40: Prevalence of Pigmentary Glaucoma (PG) in the United States for the Years 2006, 2009, & 2011 (In Thousand Individuals) (includes corresponding Graph/Chart).....III-14

Table 41: Number of Individuals Treated for Glaucoma in the United Sates (2006, 2009 and 2011): Breakdown by Type - Ocular Hypertension (OHT), Primary Open Angle Glaucoma (POAG), Normal Tension Glaucoma (NTG), Pigmentary Glaucoma (PG) and Exfoliative Glaucoma (EG) (In 000 Individuals) (includes corresponding Graph/Chart).....III-14

Table 42: Prevalence of Ocular Allergy in the United States for the Years 2006, 2009, & 2012 (In Millions of Individuals) (includes corresponding Graph/Chart).....III-14
1$200
   Table 43: Number of Individuals Treated for Ocular Allergy in the United States (In Million) for the Years 2006, 2009 & 2012 (includes corresponding Graph/Chart).....III-15

Table 44: Prevalence of Cataract in the United States: Percentage Breakdown by Age Group for the Year 2005 (includes corresponding Graph/Chart).....III-15

Table 45: Prevalence of Cataract in the United States for the Years 2006, 2009, & 2012 (In Millions of Individuals) (includes corresponding Graph/Chart).....III-15

Table 46: Number of Individuals Treated for Cataract With Ocular NSAIDs (Topical Non- Steroidal Anti-Inflammatory Drugs) in the United States for the Years 2006, 2009 & 2012 ((In Millions) (includes corresponding Graph/Chart).....III-15
1$200
   Table 47: Prevalence of Dry Eye in the United States for the Years 2006, 2009, & 2012 (In Millions of Individuals) (includes corresponding Graph/Chart).....III-16

Table 48: Number of Individuals Treated for Dry Eye in the United States (In 000s) for the Years 2006, 2009 & 2012 (includes corresponding Graph/Chart).....III-16
FDA Approvals.....III-16
5$700
   Product Launches.....III-212$150
   Strategic Corporate Developments.....III-2310$525
   Key Players.....III-337$375
   B. Market Analytics.....III-40
Table 49: US Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category – Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-40
1$200
   Table 50: US Long-term Projections for Ophthalmic Pharmaceutical Drugs by Therapeutic Category – Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-411$200
   Table 51: US 10-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart).....III-42
1$200
  2. Canada.....III-435 $575  
   A. Market Analysis.....III-43
Outlook.....III-43
Lack of Awareness: A Key Issue.....III-43
Key Players.....III-43
1$75
   Strategic Corporate Developments.....III-441$75
   B. Market Analytics.....III-45
Table 52: Canadian Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-45
1$200
   Table 53: Canadian Long-term Projections for Ophthalmic Pharmaceutical Drugs by Therapeutic Category – Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-461$200
   Table 54: Canadian 10-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category – Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart).....III-47
1$200
  3. Japan.....III-486 $675  
   A. Market Analysis.....III-48
Outlook.....III-48
Growth Drivers.....III-48
Market Data Statistics.....III-48
Leading Ophthalmic Pharmaceutical Brands In the Market.....III-48
Table 55: Japanese Market for Prescription Ophthalmic Drugs: Percentage Breakdown by Therapeutic Area – Glaucoma, Infection, Corneal Disorder, Ocular Allergy, Surgical Preparation, Steroid, Cataract, and Others. (includes corresponding Graph/Chart).....III-48
1$200
   Product Launches.....III-49
Strategic Corporate Developments.....III-49
1$75
   Key Players.....III-501$75
   B. Market Analytics.....III-51
Table 56: Japanese Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-51
1$200
   Table 57: Japanese Long-term Projections for Ophthalmic Pharmaceutical Drugs by Therapeutic Category – Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-521$200
   Table 58: Japanese 10-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart).....III-53
1$200
  4. Europe.....III-548 $875  
   A. Market Analysis.....III-54
Outlook.....III-54
A Market Primer.....III-54
Drug Reimbursement in Europe.....III-54
1$75
   Key Player.....III-551$75
   B. Market Analytics.....III-56
Table 59: European Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Country/Region – France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-56
1$200
   Table 60: European Long-term Projections for Ophthalmic Pharmaceutical Drugs by Country/Region – France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-571$200
   Table 61: European 10-Year Perspective for Ophthalmic Pharmaceutical Drugs by Country/Region – Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain and Rest of Europe Markets for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart).....III-581$200
   Table 62: European Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-591$200
   Table 63: European Long-term Projections for Ophthalmic Pharmaceutical Drugs by Therapeutic Category – Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-601$200
   Table 64: European 10-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart).....III-61
1$200
  4a. France.....III-624 $425  
   A. Market Analysis.....III-62
Outlook.....III-62
Strategic Corporate Development.....III-62
1$75
   B. Market Analytics.....III-63
Table 65: French Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-63
1$200
   Table 66: French Long-term Projections for Ophthalmic Pharmaceutical Drugs by Therapeutic Category – Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-641$200
   Table 67: French 10-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart).....III-65
1$200
  4b. Germany.....III-663 $450  
   Market Analysis.....III-66
Table 68: German Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-66
1$200
   Table 69: German Long-term Projections for Ophthalmic Pharmaceutical Drugs by Therapeutic Category – Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-671$200
   Table 70: German 10-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart).....III-68
1$200
  4c. The United Kingdom.....III-693 $450  
   A. Market Analysis.....III-69
Outlook.....III-69
Key Player.....III-69
B. Market Analytics.....III-69
Table 71: UK Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category– Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III